Sign In
Buy DYN
$17.99
+0.750 (+4.35%)
At Close: Jun 03, 2026
Why Is Dyne Therapeutics Stock Soaring On Monday?
03:53pm, Monday, 20'th May 2024
Monday, Earlier this year, released initial clinical data from both trials. In the ACHIEVE trial, patients in the 5.4 mg/kg Q8W cohort had a 27% mean splicing correction from baseline across a broad,
Why Dyne Therapeutics, With A 108% Run This Year, Just Catapulted Again
12:47pm, Monday, 20'th May 2024
Top-notch biotech stock Dyne broke out Monday after the company unveiled promising test results for a pair of muscular dystrophy drugs.
Tech Surge Boosts Nasdaq to Record Highs
11:48am, Monday, 20'th May 2024
Tech Surge Boosts Nasdaq to Record Highs The S&P 500 is wavering below all-time highs as well Laura McCandless Deputy Editor May 20, 2024 at 11:48 AM SPX|IXIC|DJI All three major indexes are higher mi
- In Phase 1/2 ACHIEVE Trial, DYNE-101 Demonstrated Dose Dependent 27% Mean Splicing Correction Across All Patients in the 5.4 mg/kg Cohort at 3 Months -
WALTHAM, Mass., May 19, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for peop
Dyne Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
04:10pm, Thursday, 02'nd May 2024
- Additional Clinical Data from ACHIEVE Trial of DYNE-101 in DM1 and DELIVER Trial of DYNE-251 in DMD Anticipated in the Second Half of 2024 -
Dyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive Officer
04:05pm, Wednesday, 27'th Mar 2024
WALTHAM, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for peo
Dyne Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium
08:30am, Wednesday, 27'th Mar 2024
WALTHAM, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for pe
Dyne Therapeutics Announces CEO Transition
07:30am, Monday, 25'th Mar 2024
- John Cox, Industry Leader with Global Experience in Rare Disease Commercialization, Joins Dyne as President and CEO -
Dyne Therapeutics to Present at Stifel 2024 Virtual CNS Days
07:30am, Wednesday, 13'th Mar 2024
WALTHAM, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for pe
Dyne: H2 2024 Muscle Disease Data Could Boost Value
02:48pm, Tuesday, 05'th Mar 2024
Dyne: H2 2024 Muscle Disease Data Could Boost Value
Dyne Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
07:30am, Tuesday, 05'th Mar 2024
- Positive Initial Clinical Data from ACHIEVE Trial in DM1 Patients and DELIVER Trial in DMD Patients Demonstrated Proof-of-Concept, Validating the Promise of the FORCE™ Platform and Targeted Delive
- Presentations will Highlight Initial Data Announced in January 2024 Demonstrating Proof-of-Concept in its DM1 and DMD Programs, Validating the Promise of the FORCE™ Platform and Targeted Delivery
Dyne Therapeutics to Present at February Investor Conferences
07:30am, Thursday, 01'st Feb 2024
WALTHAM, Mass., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for peop
7 Speculative Stocks to Double Your Money THIS Year
10:14pm, Monday, 22'nd Jan 2024
While investors should probably direct the majority of their market-earmarked funds toward slow-and-steady ideas – à la Warren Buffett – sometimes, we end up with gambling money. And in that case
